





Conjunctival Tumors (OSSN)

Miguel A. Materin, M.D.
Professor of Ophthalmology
Professor of Radiation Oncology
Division Chief Ocular Oncology



Duke Ophthalmology
Duke University School of Medicine






Disclosure


- Castle Biosciences (Advisory Board)
- Astra Zeneca (Advisory Board)
- Ideaya Biosciences (Consultant)




Ocular Surface Tumors

<u>Benign</u>	<u>Malignant</u>
<ul style="list-style-type: none">• Racial melanosis• Nevus• PAM without atypias• Papilloma• Others	<ul style="list-style-type: none">• PAM with atypias• Melanoma• Lymphoma• OSSN• Metastases• Others










Ocular Surface Squamous Neoplasia (OSSN): Treatment


• 5 FU	• IFN alfa-2b	• MMC
• DNA synthesis (-)	• Low molecular glycoprotein from WBC	• Alkylating agent
• 1% QID, 7 days	• 1 MIU/ml, QID, daily	• 0.02-0.04% QID, 7 days
• Off 3 weeks	• Resolution: 80-100%	• Off 2-4 weeks
• Resolution: 80-100%	• Irritation, conjunctivitis	• Resolution: 75-100%
• Pain, hyperemia	• Well tolerated	• Pain, corneal toxicity
• Not expensive		• Stem cell deficiency






















ELSEVIER CrossMark

Brachytherapy 22 (2023) 416–427

BRACHYTHERAPY

First clinical implementation of Yttrium-90 Disc Brachytherapy after FDA clearance

Paul T. Finger^{1,2,3*}, Robert Stewart², Mark J. Rivard³, Raymond J. Beers², Jacob Kamen², Shyam Lama², Kimberly J. Chin^{1,2}, Kyle Mohney¹, Toby S. Welles³, Wolfgang A.G. Sauerwein³, Kenneth Rosenzweig²

¹The Department of Ocular Tumor, Orbital Disease, and Ophthalmic Radiation Therapy, The New York Eye Cancer Center, New York, NY
²The Departments of Ophthalmology, Radiation Oncology, and Radiation Safety, New York Eye and Ear Infirmary of Mount Sinai and Icahn School of Medicine at Mount Sinai, New York, NY
³Scientific Advisory Board and Employees of Liberty Vision Corporation, Portsmouth, NH

> J Appl Clin Med Phys. 2023 Sep 14:e14140. doi: 10.1002/acm2.14140. Online ahead of print.

Monte Carlo dosimetry of a novel Yttrium-90 disc source for episcleral brachytherapy

Xiangyun Chang ^{1 2}, Lyu Huang ², Jian Liu ³, Yijian Cao ^{1 2 4}, Jenghwa Chang ^{1 2 4}

Affiliations + expand
PMID: 37708092 DOI: 10.1002/acm2.14140

Yttrium 90 Brachytherapy (Y90): Anterior Tumors

LV Y-90 Disc


Wand With See-Through Polymer Shield


Light Weight Ergonomic Handle


Conjunctival Squamous Cell Carcinoma



July 2023

October 2023







Summary: Y90 Plaque Brachytherapy

- Easy to use
- Fast delivery radiation (few minutes)
- Anterior and posterior tumors
- Longer follow up is needed (for results and adverse side effects)
- Tumors adjacent to optic nerve head might be a challenge
- Plaque size (6mm)
- Plaque size (10mm) hopefully this year